SynthesisJournal of epidemiology and global health2026
Global Epidemiology of Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.
Synthesis in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParoxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematological disorder characterized by chronic intravascular hemolysis and an increased risk of thrombosis. A systematic synthesis of disease epidemiology is essential to understand disease patterns, improve timely diagnosis, and guide healthcare policies. This review aims to consolidate contemporary estimates of PNH incidence and prevalence globally and describe any observed trends in these epidemiological parameters.
methodsA systematic search of electronic databases was performed in November 2024 and identified 27 studies published between 2006 and 2024 following PRISMA guidelines. All population-based observational studies reporting incidence or prevalence measures of PNH were included, with no restrictions on age or geography; the synthesis of results focused on studies evaluated as medium or high-quality based on a structured assessment.
resultsThe annual incidence of patients diagnosed with PNH ranged from 0.17 to 0.35 per 100,000 population between 2002 and 2022 in the majority of high-quality studies. Regional variability emerged: studies from countries with high healthcare system quality scores consistently reported higher incidence estimates than those from countries with low scores. Yearly prevalence estimates in 2010-2021 ranged from 1.1 to 2.1 per 100,000 population, while longer-period prevalence (10-17 years) ranged from 1.5 to 6.4 per 100,000 population. DISCUSSION: The prevalence of diagnosed PNH has been steadily growing since 2006 across all regions, possibly reflecting improved survival rates following the introduction of effective therapies or improved diagnostic practices. Despite disruptions observed during the COVID-19 pandemic (2020-2021), this upward trend is expected to continue as treatment access improves globally. The lower incidence reported in the regions with lower healthcare quality scores reflects potential underdiagnosis of PNH or unequal access to healthcare, highlighting the need for strengthening healthcare systems to ensure timely diagnosis and access to treatment of PNH.
conclusionsThis review provides updated global estimates of the incidence and prevalence of PNH, offers new insights into epidemiological trends, and highlights potential regional inequities in diagnosis and treatment. The results aim to support future research initiatives and inform healthcare strategies to improve outcomes for patients with PNH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.